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In Figure 1, as an example of the clinical-like capabilities of 
FRED, a satisfactorily comparison between the DVH obtained 
by FRED and by MCTPS [3] and a TPS commercial software is 
shown.  
  
 
Figure 5 Comparison between the DVH from Fred and ref [3] 
 
The time needed to trace the protons and optimize the dose 
is 20 s on 4x GPU NVIDA GTX 980 machine. The MC speed is 
0.33 μs/primary.  
Conclusions: The satisfactorily dosimetric agreement 
between FRED predictions and TPS/dosimetric data supports 
its future use at CNAO as fast dose recalculation tool based 
on in room patient geometry and as an independent patient 
plans verification platform.  
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In recent years, some Auger-emitting radionuclides clinically 
used for imaging/diagnostics started to be envisaged also for 
selective and targeted radiotherapy. Among the Auger-
emitting radionuclides, 125I is of particular interest, as it 
emits about 20 electrons per decay, as opposed to 4 
electrons per decay emitted by 99mTc. Nevertheless, 99mTc 
still is the most used radionuclide in diagnostic Nuclear 
Medicine; therefore, the possibility of Auger therapy with 
99mTc should open new avenues in cancer theranostics. Auger 
electrons travel a short distance within human tissues (about 
1-10 nm) and, thus, the Auger-emitting radionuclide must be 
transported to the cell nucleus to elicit DNA damage. 
Following previous encouraging results,1 we have designed 
and evaluated 99mTc(I)/Re(I) tricarbonyl complexes and 125/127I 
heteroaromatic compounds that contain an AO group for 
enhanced nuclear uptake and strong DNA intercalation. To 
have an insight on the relevance of these radiolabeled 
compounds for DNA-targeted Auger therapy we have 
investigated: i) their ability to cause DNA chain breaks; ii) 
the influence of the two different radionuclides in DNA 
damage; iii) the effect of the distance between the AO 
intercalating unit and the radioactive atom (99mTc or 125I). To 
address these issues several studies were carried out: i) 
evaluation of DNA binding and DNA damage; ii) cellular and 
nuclear internalization experiments; iii) -H2AX assays; iv) 
molecular docking and v) nanodosimetric calculations. 
Both classes of compounds are able to induce DNA double 
strand breaks (dsb) (either in plasmids or in tumor cells) but 
the extent of DNA damage (e.g. dsb yield) and the role of 
direct effects are strongly dependent on the linker used to 
attach the Auger emitting radionuclide (125I or 99mTc) to the 
AO moiety. Experimental data were corroborated by the 
docking and nanodosimetric studies; furthermore, most of 
the tested compounds presented a moderate to high uptake 
in tumor cells, with a significant accumulation in the cell 
nucleus. Altogether, these results give impetus to pursue 
with the pre-clinical evaluation of these radiolabeled AO 
derivatives as new radioactive probes for anticancer Auger 
therapy. 
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Purpose: Radiotherapy plays an important role in treatment 
of gliomas even though the clinical outcome is relatively 
poor, mainly due to local failure. A higher uniform tumour 
dose may however increase the risk of adverse effects, 
especially for lager target volumes. 
A selective boost to the 18F-fluoro-ethyl-tyrosine (FET)-PET 
active volume, might prolong time to progression without 
increasing the risk of adverse effects. The present treatment 
planning study investigate and compare the ability of three 
techniques, VMAT, IMRT and IMPT to deliver a high conformal 
high dose boost to the BTV in patients with gliomas. 
Material/methods: Seven patients with a pre therapeutic 
FET-PET/CT and MRI were used in the study.  
For each patient a standard IMRT treatment plan giving 60 Gy 
in 30 fractions to the BTV and 46 Gy to the CTV(46 Gy) was 
calculated as a benchmark. A CTV(46 Gy) was defined as 
tumor and/or tumor cavity added a 2 cm margin. The BTV 
was defined from the FET PET and covered a tumor-to-brain 
cut-off ratio of FET uptake ≥ 1.6 (pre-surgery) and ≥ 2.1 
(post-surgery). Both BTV and CTV(46 Gy) were modified to 
respect anatomic barriers. Planning target volumes (PTV), 
PTV(boost) and PTV(46 Gy) were generated by uniformly 
expanding the BTV and CTV(46 Gy), respectively with 3mm. 
The standard IMRT plans were used to define the base level 
of dose to the organs at risk (OAR) and PTV(46 Gy) 
homogeneity. To evaluate the dose to the OAR the mean 
dose was used. The PTV(46 Gy) homogeneity was defined as 
the volume of PTV(46 Gy) subtracted PTV boost which 
received more than 107% of the prescribed 46 Gy. The IMRT, 
VMAT and IMPT dose escalating treatment plans were 
optimized in order to get the highest achievable mean PTV 
boost dose, without increasing the mean dose to critical OAR 
and without decreasing the PTV(46 Gy) homogeneity. For all 
plans the dose boost was given as the integrated boost over 
30 fractions. All treatment plans were carried out using the 
Eclipse treatment planning system (Varian Medical systems, 
Palo Alto, CA, USA). 
Results: A standard IMRT plans were calculated for all 
patients and the base level for PTV(46 Gy) homogeneity was 
found to range between 65 % to 86 %, with a median value of 
77%. Dose escalating, while maintaining this homogeneity, 
was found feasible using all three techniques.  The mean 
doses to PTV(boost) were 77.1Gy, 79,2Gy and 85.1Gy for 
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IMRT, VMAT and IMPT respectively and the maximum doses 
were 82.5Gy, 87.4Gy and 89.9Gy. On top of the significant 
increase in mean and maximum PTV boost dose obtained for 
IMPT, the PTV(46 Gy) homogeneity can be improved  to a 
median value of 30.4%.  
Conclusion: Dose escalating a FET PET based target volume to 
above 77 Gy in 30 fractions by IMRT, VMAT, and IMPT without 
increasing both the PTV(46 Gy) homogeneity and the mean 
dose to the OAR was found feasible. For IMPT the PTV(46 Gy) 
homogeneity was substantially improved, implicating a 
reduction of the risk of morbidity. 
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Purpose: Published studies concerning radiotherapy at ultra 
high dose rate (Flash) show a possible increase in the 
differential response between normal and tumour tissue 
compared to conventional radiotherapy [1-2]. Since we have 
access to a prototype linac capable of pulsed electron 
irradiation at those dose rates, we have setup a research 
program to investigate the biological effects of Flash 
irradiation on normal tissues and tumours. Irradiations at 
ultra high dose rates means short (< 1 s) beam-on times with 
a very intense beam. This makes the dosimetric precision 
needed for pre-clinical studies rather challenging. The 
overall purpose of our project is to address all technical and 
dosimetric questions related to irradiation at ultra high dose 
rates, along with pre-clinical studies.  
Material and methods: The first step of the program was to 
investigate if the standard types of dosimeters can still be 
used for electron absolute dosimetry in these radiation 
intense conditions, especially for ionization chambers which 
are known to saturate. Hence, dose rate dependence was 
investigated for a wide variety of dosimeters used in 
radiotherapy by studying their response at various dose rates. 
The second step was to investigate the relative biological 
effect. Normal tissue toxicity and GBM response was studied 
in vitro and in mice after whole brain irradiation with Flash 
and at conventional dose rate.  
Results: Four of the tested dosimeters (Radiochromic film 
(Gafchromic EBT3), TLD, Alanine pellets, and a chemical 
dosimeter based on Methyl Viologen) showed no dose rate 
dependence. The response of the Advanced Markus ionization 
chamber (PTW-Freiburg) was measured to depend only on the 
dose-per-pulse and unlike most ion-chambers did not 
saturate completely in our beam. Consequently, the chamber 
can still be used after correction from ion collection 
efficiency (Figure). With the use of these dosimeters we then 
have the precision in dose delivery (uncertainty ≈ 5%) needed 
to perform pre-clinical radiobiological studies. Studies were 
conducted on Neural Stem Cells (NSCs) and showed that the 
neurogenesis was preserved at doses up to 20 Gy with FLASH, 
whereas 10 Gy was sufficient at conventional dose rate to 
totally impair the neurogenesis, at the same time point. The 
preservation of neurogenesis was associated with preserved 
cognitive skills. Studies on GBM response are ongoing.  
   
 
Conclusions: Radiotherapy treatment at ultra high dose rate 
is almost instantaneous (< 1 s) and it could be the next major 
treatment improvement in medical radiation oncology. Our 
dosimetric measurements show that a variety of standard 
dosimeters can still be used for accurate dose determination 
at these dose rates and our first pre-clinical studies show 
that FLASH irradiation induces different responses in the 
brain NSCs compared to irradiation at conventional dose rate. 
 
 
 
 
 
 
Keywords: Flash irradiation, Dosimetry 
 
References: 
[1] Favaudon V, Caplier L, Monceau V, Pouzoulet F, Sayarath 
M, Fouillade C, Poupon M F, Brito I, Hupe P, Bourhis J, Hall J, 
Fontaine J J and Vozenin M C. 2014. Ultrahigh dose-rate 
FLASH irradiation increases the differential response between 
normal and tumor tissue in mice. Science translational 
medicine. 6 245ra93. 
[2] Favaudon V, Fouillade C and Vozenin M C. 2015. Ultrahigh 
dose-rate, "flash" irradiation minimizes the side-effects of 
radiotherapy. Cancer radiotherapie : journal de la Societe 
francaise de radiotherapie oncologique. 19 526-31. 
 
173 
Extremely high-granularity digital tracking calorimeter for 
the estimation of proton energy in proton Computed 
Tomography  
H. Pettersen1, D. Röhrich2, E. Rocco3, T. Peitzmann3, O. H. 
Odland1 
1 Haukeland University Hospital 
2 University of Bergen 
3 Utrecht University 
 
A compact, high-granularity digital calorimeter detector is a 
candidate for a high-speed Bragg Peak detector, for use in 
proton Computed Tomography. Applications range from dose 
plan validation before particle therapy to proton Stopping 
Power Ratio estimates prior to dose planning. Due to the 
large number of pixels the device will be able to cope with 
large particle multiplicities, thus providing a breakthrough in 
rate capabilities. 
The development of this device profits from R&D performed 
for high-energy physics experiments. In this context, a small 
prototype, a silicon/tungsten sandwich calorimeter (4 cm x 4 
cm x 10 cm total volume) with 24 layers of Monolithic Active 
Pixels Sensors (30 µm x 30 µm pixel size) has been 
constructed [2]. As a proof of principle for its application in 
therapy, the prototype has been irradiated with therapeutic 
proton beams ranging in energy from 122 MeV to 190 MeV, 
where the protons are stopped in the detector. A similar 
setup is reproduced in the Monte Carlo code GATE/Geant4 
[3] for validation and optimization. 
Detector performance from these tests will be presented. Of 
importance is the conversion of an energy signal into a 
charge diffused binary signal, which leads to an 
